Catheter Precision (VTAK) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 25, 2025, to be held virtually, with registration required by July 24, 2025.

• Stockholders will vote on six key proposals, including director election, share issuances, a reverse stock split, and auditor ratification.

• Board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Election of one Class I director for a three-year term expiring at the 2028 annual meeting.

• Approval of issuance of up to 4,285,716 shares upon exercise of Series L Warrants.

• Approval of issuance of up to 8,574,000 shares upon conversion of Series B Convertible Preferred Stock.

• Approval of issuance of up to 257,143 shares upon exercise of 2025 Placement Agent Warrants.

• Approval of a reverse stock split at a ratio between 1-for-5 and 1-for-19, at the Board’s discretion.

• Ratification of WithumSmith + Brown, PC as independent auditor for fiscal year 2025.

• Proposals require majority approval of shares present or represented by proxy, except director election, which is by plurality.

Board of directors and corporate governance

• Board consists of four members, three of whom are independent under NYSE American standards.

• Board is divided into three classes with staggered three-year terms.

• Committees include audit, compensation, and nominating/corporate governance, all meeting independence requirements.

• Board leadership structure features an Executive Chairman who is also CEO; no lead independent director due to board size.

• Board and committees held regular meetings in 2024, with all directors attending at least 75% of meetings.